By continually reviewing prescription benefit policies and adapting them to current clinical information, employees are limited to their first exposure to addictive painkillers.
Right now, the self-funded benefits arena is echoing with discussion of the high claims trend – in conversations about benefits, in industry-related articles and at insurance events.
By not prioritizing the use of pharmacy benefit management drug rebates, the administration is hurting companies, who shoulder the burden of rising costs by all stakeholders in the supply chain.
The insurer’s 25% reduction in painkiller scripts nearly a year ahead of schedule sets new tone for managing national epidemic, catches large brokerage’s attention.
Many pharmacy benefit managers promote discounts and drug rebates that may look good on paper, but often provide no transparency of true costs. This can result in employers paying much more than they should.
